The cell therapy industry is advancing at significant pace, with these novel therapies providing curative treatments to patients who previously had little hope of survival. It is important to consider
that each cell therapy product will have its own specific challenges and complexities for managing its generation, manufacture and delivery. Rachel Griffiths of PCI identifies how an effective risk
strategy needs to be employed to manage the chain from collection of cells through production to a final product and back to the patient.